Core Insights - Hutchison China MediTech Limited (HCM) announced the renewal of its medical insurance agreements with the National Healthcare Security Administration (NHSA) for several of its drugs, effective from January 1, 2026 [1][2] - The inclusion of ELUNATE® (fruquintinib), ORPATHYS® (savolitinib), and SULANDA® (surufatinib) in the updated National Medical Insurance Drug List signifies continued support for innovative cancer treatments in China [1][2] - TAZVERIK® (tazemetostat) has been added to the inaugural Commercial Health Insurance Innovative Drug List, enhancing access to advanced therapies for patients with specific conditions [1][2] Drug-Specific Summaries - ELUNATE® is approved for use in combination with the anti-PD-1 therapy, sintilimab, for treating advanced endometrial cancer patients who have failed prior systemic anti-tumor therapy and are not suitable for curative surgery or radiotherapy [1] - ELUNATE® is also renewed for treating metastatic colorectal cancer patients who have previously received fluorouracil, oxaliplatin, and irinotecan-based chemotherapy, as well as those who have received or are unsuitable for VEGF and EGFR-targeted therapies [1] - ORPATHYS® is included for treating adults with locally advanced or metastatic non-small cell lung cancer harboring MET exon 14 alterations [1][2] - SULANDA® is renewed for treating unresectable locally advanced or metastatic, progressive, non-functional, well-differentiated (G1, G2) neuroendocrine tumors of pancreatic and non-pancreatic origin [2] - TAZVERIK® is included in the Commercial Health Insurance Innovative Drug List for adult patients with EZH2 mutation-positive relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [2] Policy and Market Implications - The NHSA's announcement of the 2025 adjustment plan for the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List highlights a focus on high-innovation, clinically valuable drugs that exceed the basic insurance coverage [2] - The establishment of the Commercial Health Insurance Innovative Drug List aims to enhance patient access to breakthrough therapies and supports the sustainable development of China's innovative pharmaceutical industry [2]

Core Viewpoint - The company reported a strong revenue growth of over RMB 3.3 billion in Q3 2025, reflecting a year-on-year increase of approximately 40%, driven by both oncology and comprehensive product lines [1] Group 1: Oncology Product Performance - The company maintains a leading position in the oncology treatment sector, with significant advantages in its product portfolio, including steady growth of key products like Dabrushe® (sintilimab injection) [1] - The contribution of innovative products to revenue has further increased, showcasing the company's focus on advanced treatment options [1] Group 2: Comprehensive Product Line Development - The comprehensive product line is rapidly releasing its potential, with significant contributions from products like Xinermy® (masitinib injection), Xinbile® (toripalimab injection), and Xinbimin® (tremelimumab N01 injection), which have shown effective market access and channel marketing results [1] - The approval of a second diabetes indication for Masitinib by the National Medical Products Administration of China enhances the company's ability to provide high-quality and accessible innovative treatment solutions to a broader patient base [1] Group 3: Strategic Vision and Pipeline - The company is committed to sustainable growth and global innovation, focusing on oncology and comprehensive product lines, including cardiovascular, metabolic, autoimmune, and ophthalmology sectors [1] - As of now, the company has obtained approvals for 16 products, with 2 under review by the National Medical Products Administration of China, 4 new drug molecules in Phase 3 or pivotal clinical studies, and approximately 15 new drug candidates in clinical research [1] - The year 2025 marks a significant milestone for the company as it enters a new phase of dual-driven growth and global innovation, aiming to become a world-class biopharmaceutical company [1]